Literature DB >> 14645203

Myopathy phenotype in transgenic mice expressing mutated PABPN1 as a model of oculopharyngeal muscular dystrophy.

Hirotake Hino1, Kimi Araki, Eiichiro Uyama, Motohiro Takeya, Masatake Araki, Kumiko Yoshinobu, Koichiro Miike, Yasuhiro Kawazoe, Yasushi Maeda, Makoto Uchino, Ken-ichi Yamamura.   

Abstract

Autosomal dominant oculopharyngeal muscular dystrophy (OPMD) is a late-onset disorder characterized clinically by progressive ptosis, dysphagia and limb weakness, and by unique intranuclear inclusions in the skeletal muscle fibers. The disease is caused by the expansion of a 10-alanine stretch to 12-17 alanine residues in the poly(A)-binding protein, nuclear 1 (PABPN1; PABP2). While PABPN1 is a major component of the inclusions in OPMD, the exact cause of the disease is unknown. To elucidate the molecular mechanism and to construct a useful model for therapeutic trials, we have generated transgenic mice expressing the hPABPN1. Transgenic mice lines expressing a normal hPABPN1 with 10-alanine stretch did not reveal myopathic changes, whereas lines expressing high levels of expanded hPABPN1 with a 13-alanine stretch showed an apparent myopathy phenotype, especially in old age. Pathological studies in the latter mice disclosed intranuclear inclusions consisting of aggregated mutant hPABPN1 product. Furthermore, some TUNEL positive nuclei were shown around degenerating fibers and a cluster of it in the lesion in necrotic muscle fibers. Interestingly, the degree of myopathic changes was more prominent in the eyelid and pharyngeal muscles. Further, muscle weakness in the limbs was apparent as shown by the fatigability test. Nuclear inclusions seemed to develop gradually with aging, at least after 1 week of age, in model mouse muscles. We established the first transgenic mouse model of OPMD by expressing mutated PABPN1, and our model mice appear to have more dramatic alternations in myofiber viability.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14645203     DOI: 10.1093/hmg/ddh017

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  13 in total

1.  A Drosophila model of oculopharyngeal muscular dystrophy reveals intrinsic toxicity of PABPN1.

Authors:  Aymeric Chartier; Béatrice Benoit; Martine Simonelig
Journal:  EMBO J       Date:  2006-04-27       Impact factor: 11.598

2.  Progressive myopathy in an inducible mouse model of oculopharyngeal muscular dystrophy.

Authors:  Ami Mankodi; Thurman M Wheeler; Reena Shetty; Kelly M Salceies; Mark W Becher; Charles A Thornton
Journal:  Neurobiol Dis       Date:  2011-09-21       Impact factor: 5.996

3.  PABPN1 suppresses TDP-43 toxicity in ALS disease models.

Authors:  Ching-Chieh Chou; Olga M Alexeeva; Shizuka Yamada; Amy Pribadi; Yi Zhang; Bi Mo; Kathryn R Williams; Daniela C Zarnescu; Wilfried Rossoll
Journal:  Hum Mol Genet       Date:  2015-06-30       Impact factor: 6.150

4.  Modeling oculopharyngeal muscular dystrophy in myotube cultures reveals reduced accumulation of soluble mutant PABPN1 protein.

Authors:  Vered Raz; Samantha Routledge; Andrea Venema; Hellen Buijze; Erik van der Wal; Seyedyahya Anvar; Kirsten R Straasheijm; Rinse Klooster; Michael Antoniou; Silvère M van der Maarel
Journal:  Am J Pathol       Date:  2011-08-18       Impact factor: 4.307

Review 5.  The long and the short of it: the role of the zinc finger polyadenosine RNA binding protein, Nab2, in control of poly(A) tail length.

Authors:  Sharon Soucek; Anita H Corbett; Milo B Fasken
Journal:  Biochim Biophys Acta       Date:  2012-03-28

6.  Novel mouse models of oculopharyngeal muscular dystrophy (OPMD) reveal early onset mitochondrial defects and suggest loss of PABPN1 may contribute to pathology.

Authors:  Katherine E Vest; Brittany L Phillips; Ayan Banerjee; Luciano H Apponi; Eric B Dammer; Weiting Xu; Dinghai Zheng; Julia Yu; Bin Tian; Grace K Pavlath; Anita H Corbett
Journal:  Hum Mol Genet       Date:  2017-09-01       Impact factor: 6.150

7.  Interactions between homopolymeric amino acids (HPAAs).

Authors:  Yoko Oma; Yoshihiro Kino; Kazuya Toriumi; Noboru Sasagawa; Shoichi Ishiura
Journal:  Protein Sci       Date:  2007-08-31       Impact factor: 6.725

Review 8.  Oculopharyngeal muscular dystrophy: a polyalanine myopathy.

Authors:  Bernard Brais
Journal:  Curr Neurol Neurosci Rep       Date:  2009-01       Impact factor: 5.081

Review 9.  PABPN1: molecular function and muscle disease.

Authors:  Ayan Banerjee; Luciano H Apponi; Grace K Pavlath; Anita H Corbett
Journal:  FEBS J       Date:  2013-05-24       Impact factor: 5.542

10.  Over-expression of BCL2 rescues muscle weakness in a mouse model of oculopharyngeal muscular dystrophy.

Authors:  Janet E Davies; David C Rubinsztein
Journal:  Hum Mol Genet       Date:  2011-01-03       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.